European Innovation Council

VSORA is an intellectual property provider based in France, specializing in digital signal processing (DSP) technology for semiconductor chips used in advanced digital communications systems, including 5G networks. Founded in 2015 by a team of experienced DSP engineers, the company offers a powerful multi-core DSP architecture that eliminates the need for DSP co-processors, allowing for greater flexibility akin to software programming. VSORA's innovative DSP development flow facilitates collaboration between signal processing and software engineers, significantly accelerating time-to-market for new products. The company focuses on enhancing DSP computing power while optimizing power consumption and performance, ultimately reducing the silicon footprint required for complex integrated circuits.

AMT Medical B.V., established in 2015 and located in Ede, the Netherlands, specializes in the development of innovative medical devices for heart bypass surgery. The company's flagship product, the AMT Heart Bypass System, utilizes a minimal invasive technique known as the ELANA bypass, which was invented by neurosurgeon Prof. Dr. C.A.F. Tulleken and his research team. This advanced technology aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, thereby improving patient outcomes and reducing complications. AMT Medical has completed the full development of its product and the production process, with all pre-clinical trials successfully concluded. The company is also preparing to initiate a clinical multi-center trial to further validate the technology's efficacy.

Sparrow Quantum Aps. is a Danish company focused on advancing quantum technology through the development of light-matter interfaces. It specializes in creating deterministic single-photon sources, which are essential for various quantum applications. The company boasts the highest efficiency in on-chip single-photon sources globally, characterized by superior photon purity, indistinguishability, and outcoupling capabilities. This innovative technology is the culmination of over twenty years of research at the renowned Niels Bohr Institute in Copenhagen, from which Sparrow Quantum holds exclusive licenses to key patents. By leveraging self-assembled quantum dots integrated with slow-light photonic-crystal waveguides, Sparrow Quantum enhances light-matter interaction, providing clients with advanced solutions for their quantum technology needs.

Marvel Fusion is a Munich-based company established in 2019 that specializes in the development of fusion energy technology. The company focuses on creating a laser-based nuclear fusion reactor designed to provide environmentally friendly and safe energy solutions. Its innovative reactor utilizes short pulse, high energy, and electrically efficient lasers, making it suitable for the commercialization of baseload fusion electrical power. By advancing this technology, Marvel Fusion aims to enable consumers to access clean, reliable energy sources, contributing to a sustainable energy future.

Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in developing advanced imaging technologies. The company focuses on light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. Wooptix's platform enables the three-dimensional modulation of images, allowing for higher data points at elevated frame rates in volumetric images and videos. This technology facilitates enhanced image quality and advanced post-processing capabilities, providing users with innovative ways to interact with and visualize their environments. Wooptix aims to improve human experiences through its cutting-edge imaging solutions.

Stablepharma Ltd is a biotechnology company based in Bath, United Kingdom, focused on developing innovative processes for vaccine stabilization. Its technology platform, StablevaX™, transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration, addressing significant challenges in cold chain logistics. By enabling pre-dosed and stable vaccine delivery, Stablepharma aims to eliminate waste and reduce costs in the distribution of medical products. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates actively with global vaccine manufacturers, academic institutions, and non-governmental organizations to advance its pipeline of thermostable solutions. Established in 2012, Stablepharma is dedicated to improving access to vaccines for children and adults, while also contributing to reduced carbon dioxide emissions in the healthcare sector.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

Photon IP is a deeptech startup located in Eindhoven, the Netherlands, specializing in the development of advanced technologies for photonics applications. The company focuses on creating application-specific semiconductors that cater to various industries, including automotive and telecommunications. Its innovative products are designed to enhance the production of wearable electronics and improve data center operations, providing tailored solutions that address the evolving needs of its clients.

GBM Works B.V., founded in 2016 and headquartered in The Hague, Netherlands, specializes in the installation of offshore wind turbine foundations. The company has developed an innovative technique known as the GBM Vibro-drill, which allows for the silent installation of these foundations. This method aims to minimize ocean noise and its impact on marine ecosystems and nearby communities, thereby facilitating the growth of the renewable energy sector's offshore operations. GBM Works combines conventional installation techniques with advanced technology to enhance the efficiency and sustainability of offshore wind energy projects.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Maynooth University is internationally recognised for quality and value of Their research and scholarship and Their dedication and commitment to teaching and Their students. Part of the NUI and formally established as an autonomous university in 1997, Maynooth University traces its origins to the foundation of the Royal College of St. Patrick in 1795, drawing inspiration from a heritage that includes over 200 years of education and scholarship. The University is a place of lively contrasts. It is a modern institution, dynamic, rapidly-growing, research-led and engaged, yet grounded in historic academic strengths and scholarly traditions.

Axelera AI is a company focused on advancing artificial intelligence through its specialized hardware and software platforms, particularly for edge computing applications. Its flagship product, the Metis™ AI Platform, combines innovative hardware and software to offer high-performance and energy-efficient AI inference solutions. Recognized for its innovation, the platform was honored at the CES® 2024 Innovation Awards. Established in 2021, Axelera AI was incubated by Bitfury, a leader in emerging technologies, and partnered with imec, a prominent nano-technology group. The company is headquartered in the AI Innovation Center at the High Tech Campus in Eindhoven, with research and development offices located in Belgium, Switzerland, and Italy. The team consists of experts in AI software and hardware, many of whom have backgrounds with leading AI firms and Fortune 500 companies. Axelera AI’s platform features a unique custom dataflow architecture with multicore in-memory computing, enabling clients to achieve optimal power efficiency while supporting various networks for sustainable edge applications.

Qblox is a Dutch scaleup specializing in quantum technology, focused on developing patented solutions for the scalable control of quantum computers. The company designs and manufactures modular control hardware that simplifies the experimental setups involving qubits, employing a distributed processor architecture to enhance gate fidelities. By advancing electronics with improved noise and drift performance, Qblox enables scientists to minimize crosstalk and achieve low-latency arbitrary control flows while optimizing measurement efficiency in dynamic readout conditions. The company aims to address the scientific and engineering challenges that must be overcome to transition from prototype quantum computers to powerful, practical quantum processors.

King's College London is a public research university in London, United Kingdom, and a constituent college of the University of London. Founded in 1829 by King George IV and the Duke of Wellington, it operates from multiple central London campuses and a campus in Denmark Hill, with a strong emphasis on medical and biomedical research and education. The institution supports a large community of students and staff and is known for its extensive graduate and postgraduate programmes. It is a founding member of the King's Health Partners academic health sciences centre and participates in major research and academic networks, including the Russell Group and Universities UK.

Tilkal is a Paris-based company founded in 2017 that specializes in supply chain traceability and trust solutions for Industry 4.0. The company has developed a software infrastructure that organizes traceability data across various supply chain stakeholders, utilizing a unique B2B blockchain network to facilitate secure and verifiable data sharing. Tilkal's platform incorporates analytics and scoring algorithms to provide an end-to-end, real-time representation of supply chains. This enables businesses to address critical questions regarding product location, sourcing risks, ESG commitments, and compliance verification. Prominent clients include Danone, Daher, Joone, and the NGO Responsible Mica Initiative, which leverage Tilkal's capabilities for diverse applications such as tracing infant milk sourcing and analyzing mica supply chains. The Tilkal network comprises over 70 independent nodes and serves nearly 700 companies, reinforcing its role in promoting resilience, sustainability, and ethical practices within supply chains.

E-peas SA is a Belgian company established in 2014, specializing in the design and manufacturing of electronic systems that provide energy autonomy for Internet of Things (IoT) applications. The company develops innovative energy harvesting solutions that enable devices to draw energy from various ambient sources, including solar, thermal, vibration, and radiofrequency. E-peas produces energy harvesting power management integrated circuits (PMICs) and microcontrollers that enhance the performance and longevity of IoT devices by either extending battery life or eliminating the need for batteries altogether. Their technology caters to a wide range of sectors, including home automation, healthcare, retail, and agriculture, thereby facilitating the creation of smarter and more energy-efficient connected devices. Headquartered in Mont-Saint-Guibert, Belgium, E-peas aims to transform the landscape of portable energy solutions.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Multiverse Computing SL is a software development company based in San Sebastian, Spain, with an additional office in Toronto, Canada. Established in 2019, the company specializes in creating quantum computing software that leverages probabilistic and nondeterministic technologies to address complex challenges in various sectors, particularly finance. Multiverse Computing's software solutions are designed for portfolio optimization, risk analysis, and market simulation, enabling clients in industries such as banking, energy, manufacturing, and logistics to harness the power of quantum computing. By focusing on these tailored applications, the company aims to facilitate advancements in solving financial and macro-economic problems, positioning itself as a key player in the emerging quantum technology landscape.

Daze is an engineering startup focused on creating innovative solutions for electric vehicle charging. Its flagship product, DazePlug, is an automatic charging device that utilizes smart charging ecosystems and energy management systems. This technology enables automatic inductive charging, significantly reducing the time required to charge electric vehicles while eliminating the need for manual handling of cables. DazePlug features a retrofit design that is both waterproof and dustproof, ensuring durability and ease of use. By simplifying the charging process, Daze aims to enhance user experience and convenience for electric vehicle owners.

Palobiofarma is a Spanish biotechnology company based in Barcelona’s Science Park, dedicated to discovering and developing innovative drugs that target adenosine receptors. The company aims to be the first European entity to bring an adenosine modulator to market, focusing on the treatment of diseases such as advanced prostate cancer. Through its expertise in medicinal chemistry and in vitro pharmacology, Palobiofarma is committed to advancing the understanding of adenosine's role in disease and enabling healthcare professionals to improve patient outcomes through novel therapeutic options.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

Ignion is an antenna innovator based in Sant Cugat del Vallès, Spain, founded in 2015. The company specializes in the manufacturing of multiband, multipurpose antennas designed to address mobile and wireless connectivity needs. Ignion provides off-the-shelf antennas that cater to the Internet of Things and short-range wireless devices, particularly suited for indoor environments. Their products are designed for easy and efficient integration into industrial designs, enabling clients to meet their connectivity requirements effectively.

ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.

VSORA is an intellectual property provider based in France, specializing in digital signal processing (DSP) technology for semiconductor chips used in advanced digital communications systems, including 5G networks. Founded in 2015 by a team of experienced DSP engineers, the company offers a powerful multi-core DSP architecture that eliminates the need for DSP co-processors, allowing for greater flexibility akin to software programming. VSORA's innovative DSP development flow facilitates collaboration between signal processing and software engineers, significantly accelerating time-to-market for new products. The company focuses on enhancing DSP computing power while optimizing power consumption and performance, ultimately reducing the silicon footprint required for complex integrated circuits.

SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on advancing treatment options for patients with chronic wounds. Founded in 2017, the company is developing Aurase, a hydrogel designed to enhance wound bed preparation through the application of a recombinant enzyme derived from maggots. This innovative approach aims to facilitate wound debridement, a crucial therapeutic procedure that removes dead, damaged, or infected tissue, thereby accelerating the healing process. By leveraging biomimicry and evidence-based medicine, SolasCure seeks to improve patient outcomes across various healthcare settings.

FarmInsect GmbH, established in 2019 and headquartered in Bergkirchen, Germany, specializes in automated insect breeding systems. The company develops machines and IoT solutions that enable regional farmers to rear insects on-site for use as animal feed, primarily for chickens, pigs, and fish. This sustainable approach aims to replace imported soy or fishmeal with locally produced protein feed, thereby enhancing the efficiency of animal husbandry while reducing environmental impact.

Nanogence SA is a Swiss company established in 2017, specializing in the development of innovative material solutions for the construction sector. Based in Renens, the company focuses on creating synthetic, tailor-made materials utilizing advanced nanotechnology and chemistry. Its patented additive formulations enhance the performance of cement and concrete, significantly improving their binding efficiency while also aiming to reduce carbon emissions by up to 50%. By providing environmentally friendly chemicals and additives, Nanogence enables manufacturers in the construction industry to lower costs, enhance durability, and contribute to sustainable practices. The company operates within a rapidly growing global construction market, which underscores the importance of its contributions to more efficient and eco-friendly building materials.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

Swisspod Technologies SA is a transportation development firm based in Monthey, Switzerland, founded in 2019. The company specializes in designing and developing energy-efficient Hyperloop systems, which are innovative tube-based transportation solutions aimed at providing high-speed travel between distant cities. Swisspod's Hyperloop pods are fully electric and designed to be sustainable and affordable, emphasizing environmental responsibility and economic viability. The firm is committed to advancing high-speed transportation through cutting-edge Swiss engineering and is assembling a team of multidisciplinary experts dedicated to revolutionizing the future of travel.

Microsure is a medical device company based in Eindhoven, The Netherlands, founded in 2014. It specializes in the development of innovative solutions for microsurgery, focusing on enhancing surgical performance through its motion stabilizer system. This device assists microsurgeons by scaling down motion and filtering out tremors, thereby providing extraordinary control and precision during procedures. The system aims to improve the quality of microsurgical operations, enabling the exploration of new and highly accurate surgical techniques that were previously unavailable. Microsure's technology has been successfully tested in clinical trials, demonstrating its effectiveness in lymphedema surgeries. By facilitating the use of surgeons' own micro-instruments, the device also aims to reduce costs for healthcare facilities while increasing the number of treatment options available for patients.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Creating transformative change in urban mobility, making our cities cleaner and more enjoyable. We first focus on urban logistics, moving goods around the city in ways that are sustainable, efficient and cost-effective. Our vehicle and its modular platform system, with easily swappable modular units, meets the needs of city logistics. From moving food to flowers to furniture, the possibilities are endless. ONO’s founders, pioneer in e-mobility solutions, Beres Seelbach, former head of design at Mercedes and Volkswagen, Murat Günak, and light electric vehicle expert and engineer, Philipp Kahle, sought to rethink and reshape modern urban transportation. They put together a forward-thinking group of designers, engineers and creative thinkers who shared their vision of transforming urban mobility. ONO is a Berlin-based e-mobility company introducing a whole new category of emissions-free vehicle: the Pedal Assisted Transporter (PAT), combining the flexibility of a bicycle with the capacity and durability of a van. We offer environmentally friendly urban logistics solutions designed and optimised for cities of today.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in developing advanced imaging technologies. The company focuses on light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. Wooptix's platform enables the three-dimensional modulation of images, allowing for higher data points at elevated frame rates in volumetric images and videos. This technology facilitates enhanced image quality and advanced post-processing capabilities, providing users with innovative ways to interact with and visualize their environments. Wooptix aims to improve human experiences through its cutting-edge imaging solutions.

Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in developing advanced imaging technologies. The company focuses on light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. Wooptix's platform enables the three-dimensional modulation of images, allowing for higher data points at elevated frame rates in volumetric images and videos. This technology facilitates enhanced image quality and advanced post-processing capabilities, providing users with innovative ways to interact with and visualize their environments. Wooptix aims to improve human experiences through its cutting-edge imaging solutions.

ADmit Therapeutics, S.L. is a biotechnology company based in Begues, Spain, focused on developing diagnostic tests for the early detection of Alzheimer’s disease. Founded in 2017, the company utilizes epigenetic analysis of blood samples to identify a series of mitochondrial biomarkers, which are unrelated to traditional markers such as ß-amyloid or tau. By employing next-generation sequencing to analyze methylcytosines in mitochondrial DNA, ADmit Therapeutics provides medical practitioners with a simplified method for detecting early-stage Alzheimer’s disease. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in the accelerated identification of potential curative drugs.

Plasmacure, headquartered in Eindhoven, Netherlands, is a medical technology company focused on developing innovative solutions for chronic wound healing, with a particular emphasis on diabetic foot wounds. The company's core product is a patented cold plasma solution designed to kill bacteria, stimulate cell proliferation, and improve microcirculation, thereby reducing the risk of amputation and enhancing patients' quality of life.

EBAMed SA is a Swiss startup based in Geneva that specializes in developing innovative medical devices for the non-invasive treatment of heart arrhythmias. Founded in 2018, the company focuses on creating an ultrasound-based device that utilizes proton therapy to monitor heart motion and synchronize therapeutic beams in real time. This technology allows for the precise delivery of radiation treatment to targeted heart tissues, thereby expanding treatment options for existing proton therapy centers and enabling them to treat heart patients effectively. By providing a non-invasive approach to cardiac care, EBAMed aims to improve patient outcomes and streamline treatment processes in outpatient settings.

TreaTech is a Swiss cleantech company established in 2015 by engineers from the École Polytechnique Fédérale de Lausanne (EPFL). The company specializes in developing catalytic hydrothermal gasification (cHTG) technology that offers an innovative approach to wastewater treatment. This thermochemical process effectively transforms various types of liquid waste, including sewage sludge, into valuable by-products such as renewable gas, clean water, and mineral salts. TreaTech's solutions focus on eco-friendly waste disposal, aligning with sustainable development and circular economy principles. By recycling wastewater and its by-products, TreaTech enables clients to manage waste more sustainably while generating resources like fertilizers and biogas.

Sparrow Quantum Aps. is a Danish company focused on advancing quantum technology through the development of light-matter interfaces. It specializes in creating deterministic single-photon sources, which are essential for various quantum applications. The company boasts the highest efficiency in on-chip single-photon sources globally, characterized by superior photon purity, indistinguishability, and outcoupling capabilities. This innovative technology is the culmination of over twenty years of research at the renowned Niels Bohr Institute in Copenhagen, from which Sparrow Quantum holds exclusive licenses to key patents. By leveraging self-assembled quantum dots integrated with slow-light photonic-crystal waveguides, Sparrow Quantum enhances light-matter interaction, providing clients with advanced solutions for their quantum technology needs.

Naco Technologies Ltd is a manufacturer and supplier of advanced nano-coating technologies, specializing in high-performance coatings for various industries including tooling, automotive, aerospace, and microchip production. Founded in 2009 and headquartered in Riga, Latvia, Naco develops multilayer and multicomponent coatings that enhance equipment performance by providing oil-enhanced, wear-protective, thermal barrier, and liquid-repellent properties. The company plays a significant role in the hydrogen sector by creating specialized coatings for Green Hydrogen systems, such as electrolyzers and fuel cells, which improve the reliability of these systems while minimizing the use of costly and scarce materials. In 2015, Naco Technologies was acquired by the Schaeffler Group, a Germany-based company, further strengthening its capabilities and market reach.

Bluedrop Medical, established in 2014 and headquartered in Galway, Ireland, specializes in the development, manufacturing, and commercialization of an IoT-enabled device for early detection of diabetic foot ulcers. Their home-based system scans patients' feet daily, transmitting data to the cloud for analysis via advanced algorithms, which can identify skin abnormalities. This innovation aims to reduce the risk of amputation and improve the lives of diabetic patients, with a significant global market given the high prevalence of diabetic foot ulcers.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Nemysis Limited is a specialty pharmaceutical company based in Dublin, Ireland, founded in 2005. The company focuses on addressing unmet needs in nutritional disorders and deficiencies through a staged approach to product development. Nemysis manufactures food supplements, medical matrix products, and prescription items, targeting the same conditions across different market segments. Among its innovative offerings are a gastric and trypsin-resistant glutenous product for oral enzymatic therapy aimed at celiac disease patients, as well as an iron supplement designed to minimize gastrointestinal side effects associated with iron supplementation. Additionally, the company is developing a glutenous medical device that effectively destroys gluten, helping to prevent symptoms in individuals with celiac disease and non-celiac gluten sensitivity.

nyris GmbH is a Berlin-based company that specializes in developing a visual search platform designed to enhance product discovery by allowing users to search for items using images and videos. Established in 2015, nyris employs advanced technologies such as artificial intelligence and neural networks to deliver search results in under one second. This innovative platform serves a diverse clientele across various sectors, including retail and e-commerce, industrial and manufacturing, media and entertainment, and financial services. By facilitating a more intuitive search experience, nyris helps organizations improve efficiency and reduce friction associated with traditional text-based search methods. The company operates additional locations in Dusseldorf and has established a global presence, serving customers in over 50 countries.

Wingtra AG is a Swiss company specializing in the manufacturing of vertical take-off and landing (VTOL) drones, particularly the WingtraOne model. Founded in 2014 and headquartered in Zürich, WingtraOne is designed for high-precision aerial data collection, serving various industries such as surveying, agriculture, forestry, and infrastructure. Since its introduction to the market in 2017, the drone has gained recognition for its capability to facilitate the digitization of environments, particularly for surveying professionals in sectors including construction, mining, environmental monitoring, and urban planning. Wingtra has established partnerships with over 50 leading surveying equipment dealers worldwide, enhancing its presence in the global market. The drone operates with WingtraPilot software, enabling users to collect survey-grade aerial data that can be transformed into detailed two-dimensional maps and three-dimensional models, thereby providing valuable insights for monitoring and inspection activities across multiple industries.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in deep thermotherapy specifically for head and neck cancer treatment. The company has developed a unique medical device that employs proprietary thermal technology and interactive software to provide localized heating, enhancing the effectiveness of conventional therapies like radiotherapy and chemotherapy, which often have toxic side effects. Sensius' innovative approach has shown promising results, with a study indicating that 81.8% of treated patients achieved a complete response within 12 weeks of radiotherapy. With interest from twenty potential buyers, Sensius is in the process of obtaining CE marking for its device and has plans to expand its applications to other types of cancer in the future.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in deep thermotherapy specifically for head and neck cancer treatment. The company has developed a unique medical device that employs proprietary thermal technology and interactive software to provide localized heating, enhancing the effectiveness of conventional therapies like radiotherapy and chemotherapy, which often have toxic side effects. Sensius' innovative approach has shown promising results, with a study indicating that 81.8% of treated patients achieved a complete response within 12 weeks of radiotherapy. With interest from twenty potential buyers, Sensius is in the process of obtaining CE marking for its device and has plans to expand its applications to other types of cancer in the future.

Valo Therapeutics is an immunotherapy company focused on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Founded in 2016 and based in Oxford, United Kingdom, with an additional office in Helsinki, Finland, the company utilizes its innovative Valo Tx platform, which includes PeptiCRAd, an engineered human oncolytic adenovirus. This platform is designed to induce systemic anti-tumor T cell responses by transforming oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without requiring the production of multiple genetically modified viruses. Valo Therapeutics is also advancing other neoantigen strategies, including PeptiENV, in collaboration with Professor Vincenzo Cerullo from the University of Helsinki, to enhance therapeutic responses against various cancer types.

Kvantify is a company based in Copenhagen, Denmark, that specializes in quantum computing management software aimed at addressing complex computational challenges across various sectors, including life sciences, financial services, and logistics. Founded in 2022, Kvantify focuses on developing solutions that enhance the efficiency of processes such as drug discovery by utilizing advanced computational drug technology. This technology employs proprietary physics-based methods to improve the quality of compounds tested in laboratories, enabling life sciences companies to expedite small molecule research and achieve actionable results. Through its innovative platform, Kvantify aims to deliver significant value to its clients by solving intricate problems in their respective fields.

N2 Applied is a Norwegian technology company focused on enabling farmers to produce their own sustainable fertilizer through an innovative process that utilizes slurry, air, and electricity. The company is in the pre-commercial phase and has developed a technology that allows for the local production of nitrogen-rich fertilizer from liquid organic substrates, such as livestock manure. By integrating nitrogen from the atmosphere into these substrates, N2 Applied's solution not only enhances the nitrogen content but also mitigates ammonia loss and reduces greenhouse gas emissions. The company operates its head office in Oslo/Asker and maintains a test center in Svene, with additional branches in Wageningen and York. N2 Applied's scalable process aims to eliminate the lengthy and costly supply chains associated with traditional fertilizer production, facilitating a more circular farming system. This approach not only provides farmers with cost-effective and environmentally friendly fertilizer but also contributes to on-farm reductions in methane and ammonia emissions.

Ganymed Robotics SAS, established in 2018 and headquartered in Paris, France, specializes in the development of advanced robotics technologies tailored for orthopedic surgeons. The company's primary focus is on creating a therapeutic device designed to enhance surgical precision during knee replacement procedures. This innovative technology aims to improve patient outcomes, surgeon experience, and overall efficiency of care delivery by leveraging robotic assistance to reduce operating time.

Daze is an engineering startup focused on creating innovative solutions for electric vehicle charging. Its flagship product, DazePlug, is an automatic charging device that utilizes smart charging ecosystems and energy management systems. This technology enables automatic inductive charging, significantly reducing the time required to charge electric vehicles while eliminating the need for manual handling of cables. DazePlug features a retrofit design that is both waterproof and dustproof, ensuring durability and ease of use. By simplifying the charging process, Daze aims to enhance user experience and convenience for electric vehicle owners.

iThera Medical is a biotechnology company founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, specializing in photonic molecular imaging technology. The company focuses on the development of its proprietary multispectral optoacoustic tomography (MSOT) technology, which offers real-time visualization of anatomical, functional, and molecular information in living tissues. This innovative imaging solution enhances the ability of healthcare professionals to detect tumors and inflammatory diseases non-invasively, thereby facilitating preclinical and clinical trials. By advancing its technology, iThera Medical aims to improve diagnostic capabilities and patient outcomes in the medical field.

Resistell AG is a Swiss company founded in 2018, based in Muttenz, specializing in the development and marketing of innovative diagnostic devices for antibiotic susceptibility testing. The company's platform employs advanced nanomotion technology to detect the movement of living bacterial cells, allowing for the rapid identification of bacterial resistance to antibiotics. This method serves as an alternative to traditional culture-based antibiograms, enabling healthcare providers to administer appropriate antibiotics in a timely manner, ultimately improving patient outcomes.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

Nano4Imaging GmbH, established in 2011 and located in Aachen, Germany, specializes in the development and production of contrast agents and devices designed for in-vivo imaging of medical implants and minimally invasive devices. The company offers a range of products, including MRWire EmeryGlide, a magnetic resonance imaging (MRI) conditional guidewire, and various coatings under the MagnaFy brand that enhance the visibility of devices in different imaging modalities, such as MRI, computed tomography (CT), and X-ray. These innovations facilitate navigation and monitoring during medical interventions, particularly in the treatment of cardiovascular diseases and in radiotherapy. By leveraging advanced nanotechnology, Nano4Imaging aims to improve the accuracy of patient monitoring and intervention outcomes.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

Precisis is a medical device company founded in 2004 and headquartered in Heidelberg, Baden-Württemberg, Germany. The company focuses on developing innovative products aimed at treating epilepsy and enhancing patients' quality of life. Its flagship device provides individualized brain stimulation through a surgical procedure that places the device beneath the scalp, precisely targeting the origin of epileptic activity in the brain. This technology allows for the delivery of therapeutic currents to specific areas, enabling effective treatment without direct contact with brain tissue.

Dimenco B.V. is a prominent 3D technology company based in Veldhoven, the Netherlands, specializing in autostereoscopic solutions that enhance visual experiences without the need for glasses. Founded in 2010, Dimenco develops advanced 3D displays and components, alongside software and content conversion services tailored for both professional and consumer markets. The company's innovative offerings include DirectX and OpenGL visualizers that facilitate the viewing of 3D applications on their specialized displays, as well as tools like the Dimenco 3D Player for playing 3D video clips and the Dimenco Control Tool for adjusting visualization parameters. Dimenco has established itself as a leader in providing immersive and realistic visual technology, making significant strides in the realm of simulated reality.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

ABCDx SA is a privately-funded company based in Geneva, Switzerland, founded in 2014 by three experts in the field of brain biomarkers. The founders include two prominent researchers from the Faculty of Medicine at the University of Geneva and the Vall d’Hebron Research Institute, who are recognized for their contributions to biomarker discovery and validation. The third founder brings extensive experience in the diagnostic and pharmaceutical industries. ABCDx specializes in the development and validation of biomarker and biomarker panel tests aimed at enhancing the diagnosis and treatment of brain injuries. The company's offerings are designed to identify and assess patients at risk of severe long-term complications stemming from traumatic injuries, strokes, and post-stroke infections. Through its innovative approach, ABCDx aims to improve patient outcomes in the realm of brain health.

Nexdot is a company specializing in the development and production of semiconductor nanocrystals known as Quantum Dots, with a particular focus on nanoplatelets—two-dimensional nanosheet Quantum Dots that exhibit enhanced properties. Originating as a spin-off from a renowned academic laboratory in Paris, Nexdot leverages over a decade of expertise in nanomaterial research. The company has invested four years in intensive research and development to establish unique capabilities in the synthesis of colloidal Quantum Dots and Nanoplatelets. Their proprietary materials, characterized by controlled shape and composition, are designed for a variety of applications, including displays, lighting, energy storage, detectors, and bio-imaging. Nexdot combines a team of highly skilled, passionate scientists with seasoned executives who possess a strong background in management and innovation leadership, positioning the company as a leader in the field.

Alesi Surgical Ltd. is a company based in Cardiff, United Kingdom, specializing in the development and commercialization of laparoscopic surgical smoke handling systems. Founded in 2009 as a spin-out from the Welsh Institute for Minimal Access Therapy, Alesi Surgical focuses on creating products that enhance the safety, efficiency, and outcomes of surgical procedures. Its innovative tools are portable and suitable for both laparoscopic and robot-assisted surgeries, utilizing electrostatic precipitation technology to eliminate surgical smoke and maintain a clear visual field during operations. The company distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia, leveraging its access to experienced surgeons and surgical trainers to identify challenges in surgical procedures and design effective solutions.

ScanTrust SA is a company specializing in a cloud-based IoT platform that enhances supply chain visibility and product authentication. Founded in 2014 and headquartered in Lausanne, Switzerland, with operations in Shanghai, Singapore, and Bangkok, ScanTrust employs secure unique identifiers to connect products and packaging to the Internet. Its offerings include a printer portal for packaging and label partners to integrate secure codes into existing processes, an online portal for real-time business intelligence and supply chain insights, and secure QR codes that can be verified by smartphones. This technology enables brand owners to protect their products from counterfeiting while providing detailed supply chain control and opportunities for consumer engagement.

FOx Biosystems is a biotechnology company focused on enhancing biomolecular interaction analysis for life science research and industry. Founded in 2017 by Filip Delport and Jeroen Lammertyn, and based in Temse, Oost-Vlaanderen, Belgium, the company specializes in developing custom applications, including probes and devices, to support various research needs. FOx Biosystems employs real-time, label-free analysis technology that offers significant advantages over traditional biomolecular analysis tools, such as ease of use, speed, and cost-effectiveness. This technology enables healthcare companies and researchers to obtain high-quality biomolecular data, including concentration measurements, affinity data, and kinetic data, ultimately aiming to transform the life sciences sector.

ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human models through advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed a suite of simulation tools known as Alya Red. This platform operates on a Software-as-a-Service model and is designed for the medical device and pharmaceutical industries. Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients, utilizing high-performance computing, computational biomechanics, and data analysis. These virtual avatars enable biomedical companies and healthcare professionals to enhance diagnostics, plan treatments, optimize drug delivery, and improve medical devices.

IonKraft, a German technology company, specializes in plasma coating for multi-material plastic containers. Their innovative plasma-enhanced chemical vapor deposition process enables recyclability of complex packaging, serving industries such as food, pharmaceuticals, cosmetics, and chemicals. By promoting material reduction and reuse, IonKraft aims to enhance performance while lowering costs, with support from the German Federal Ministry for Economic Affairs and Energy.

Deep Render Ltd. is a London-based AI startup that specializes in developing advanced media compression algorithms. Originating as a spin-out from the Department of Computing at Imperial College London, the company focuses on leveraging proprietary and patented technology to enhance media compression through deep learning techniques. Its innovative approach includes the application of density estimation, unsupervised learning, and quantum methods, resulting in state-of-the-art Biological Image Compression that achieves a minimum of 50% efficiency improvement over existing standards. Additionally, Deep Render is recognized for creating the first AI codec capable of real-time video playback, which allows for enhanced market opportunities and significant cost reductions for users.

CAILabs SAS is a French deep tech company headquartered in Rennes, specializing in the design, development, and production of photonic solutions aimed at optimizing light utilization in various applications. Established in 2013, CAILabs focuses on innovative optical components, particularly through its patented Multi-Plane Light Conversion (MPLC) technology. The company provides a range of products, including mode multiplexers, light converters, and laser beam shaping solutions tailored for the telecommunications and industrial laser sectors. Its offerings are designed to enhance the performance of fiber optic networks and laser material processing, addressing critical challenges such as atmospheric turbulence and the need for efficient signal multiplexing. CAILabs aims to leverage its expertise and technological innovations to create reliable and cost-effective solutions for clients in the photonics industry.

Creating transformative change in urban mobility, making our cities cleaner and more enjoyable. We first focus on urban logistics, moving goods around the city in ways that are sustainable, efficient and cost-effective. Our vehicle and its modular platform system, with easily swappable modular units, meets the needs of city logistics. From moving food to flowers to furniture, the possibilities are endless. ONO’s founders, pioneer in e-mobility solutions, Beres Seelbach, former head of design at Mercedes and Volkswagen, Murat Günak, and light electric vehicle expert and engineer, Philipp Kahle, sought to rethink and reshape modern urban transportation. They put together a forward-thinking group of designers, engineers and creative thinkers who shared their vision of transforming urban mobility. ONO is a Berlin-based e-mobility company introducing a whole new category of emissions-free vehicle: the Pedal Assisted Transporter (PAT), combining the flexibility of a bicycle with the capacity and durability of a van. We offer environmentally friendly urban logistics solutions designed and optimised for cities of today.

ROSI is a company based in Grenoble, France, focused on developing innovative technologies for the recycling and revalorization of raw materials within the photovoltaic industry. The company specializes in recovering ultra-pure silicon and other metals that are typically lost during the manufacturing of photovoltaic cells and at the end of a solar panel's life cycle. By addressing industrial waste generated during the solar wafer slicing process and capturing silicon fine particles lost during PV-silicon production, ROSI enables its clients to produce photovoltaic modules in a more sustainable and cost-effective manner.

APIX Analytics is a company specializing in the development and marketing of advanced gas analyzer systems. Founded in 2014 and based in Grenoble, France, APIX Analytics focuses on creating miniaturized multigas analyzers using nano-silicon technology. These systems are designed for industrial, environmental, and security applications, integrating analytical chains such as sampling, gas injection, and separation of complex gas mixtures to enhance specificity and detection. The company's technology aims to improve the identification and quantification of each compound in a mixture, thereby increasing safety and quality requirements for various industries, including renewable energy development.

Positrigo AG is a Zurich-based company specializing in the development, manufacturing, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on providing functional imaging solutions that facilitate the early detection of neurodegenerative diseases, particularly Alzheimer's disease, as well as other conditions like Lewy body dementia, vascular dementia, and frontotemporal dementia. The company's PET scanners are designed to be accessible and affordable, enabling healthcare professionals to diagnose and monitor treatment effectively, while also contributing to the advancement of new therapies in the field of neurology.

Ostoform Limited is a medical device company based in Dublin, Ireland, specializing in products designed to manage skin complications for individuals with ostomies. Founded in 2016 as a spin-out from the University of Limerick, Ostoform has developed patented technologies aimed at enhancing ostomy skin health. Its flagship products include a mouldable seal that fits securely around the stoma, preventing corrosive output from contacting the skin, and FLOWASSIST, which directs stoma output away from the skin to minimize irritation and swelling. By addressing these significant challenges faced by ostomy patients, Ostoform aims to improve comfort and overall quality of life, positioning itself as a potential leader in the global ostomy care market.

Celeris Therapeutics is an AI-first drug discovery company that focuses on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address high unmet medical needs in diseases like Parkinson's and various cancers. The company has created the Celeris One platform, which utilizes structure-based geometric deep learning to enhance the design and development of degraders by prioritizing specific E3 ligases, designing effective linkers, and selecting optimal compounds for synthesis. Additionally, Celeris Therapeutics operates an in-house automated laboratory that facilitates rapid generation of experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to discover and develop small-molecule degrader therapies across multiple therapeutic areas, while also advancing its own internal drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Fineheart is a France-based medical device company specializing in innovative technologies for cardiovascular care. It focuses on the development of implantable cardiac devices aimed at treating cardiovascular diseases. The company's flagship product is a novel, wirelessly powered, fully implantable mechanical circulatory support device. This device is designed to optimize cardiac output while preserving the heart's natural contractility, thereby enabling patients to restore normal cardiac function. Fineheart's technology aims to improve the quality of life for heart failure patients, allowing them to return to normal daily activities.

Fineheart is a France-based medical device company specializing in innovative technologies for cardiovascular care. It focuses on the development of implantable cardiac devices aimed at treating cardiovascular diseases. The company's flagship product is a novel, wirelessly powered, fully implantable mechanical circulatory support device. This device is designed to optimize cardiac output while preserving the heart's natural contractility, thereby enabling patients to restore normal cardiac function. Fineheart's technology aims to improve the quality of life for heart failure patients, allowing them to return to normal daily activities.

Tilkal is a Paris-based company founded in 2017 that specializes in supply chain traceability and trust solutions for Industry 4.0. The company has developed a software infrastructure that organizes traceability data across various supply chain stakeholders, utilizing a unique B2B blockchain network to facilitate secure and verifiable data sharing. Tilkal's platform incorporates analytics and scoring algorithms to provide an end-to-end, real-time representation of supply chains. This enables businesses to address critical questions regarding product location, sourcing risks, ESG commitments, and compliance verification. Prominent clients include Danone, Daher, Joone, and the NGO Responsible Mica Initiative, which leverage Tilkal's capabilities for diverse applications such as tracing infant milk sourcing and analyzing mica supply chains. The Tilkal network comprises over 70 independent nodes and serves nearly 700 companies, reinforcing its role in promoting resilience, sustainability, and ethical practices within supply chains.

Tilkal is a Paris-based company founded in 2017 that specializes in supply chain traceability and trust solutions for Industry 4.0. The company has developed a software infrastructure that organizes traceability data across various supply chain stakeholders, utilizing a unique B2B blockchain network to facilitate secure and verifiable data sharing. Tilkal's platform incorporates analytics and scoring algorithms to provide an end-to-end, real-time representation of supply chains. This enables businesses to address critical questions regarding product location, sourcing risks, ESG commitments, and compliance verification. Prominent clients include Danone, Daher, Joone, and the NGO Responsible Mica Initiative, which leverage Tilkal's capabilities for diverse applications such as tracing infant milk sourcing and analyzing mica supply chains. The Tilkal network comprises over 70 independent nodes and serves nearly 700 companies, reinforcing its role in promoting resilience, sustainability, and ethical practices within supply chains.

AugmedIT B.V. is a medical software company founded in 2018 and located in Amsterdam, the Netherlands. The company specializes in developing augmented and mixed reality tools that enhance surgical procedures by enabling surgeons to create holograms of patients. AugmedIT's technology focuses on applications in neurosurgery, medical education, holographic visualization, and neuronavigation, aiming to improve precision and outcomes in medical practice through innovative visualization techniques.

IRUBIS GmbH, founded in 2017 and headquartered in Munich, Germany, specializes in the development of advanced mid-infrared (MIR) spectrometers and attenuated total reflection (ATR) crystals. The company integrates semiconductor technology with infrared spectroscopy to create instruments designed for real-time monitoring of bioprocesses, particularly in the pharmaceutical sector. Its offerings include a measurement system that enables online monitoring of glucose and lactate in bioreactors without contamination risk, as well as a range of ATR crystals that enhance the capabilities of Fourier transform infrared (FTIR) spectrometers. IRUBIS aims to set a new standard for online control in bioprocessing through its innovative MIR spectroscopy solutions, facilitating continuous monitoring and control of nutrient concentrations and other critical parameters in laboratory settings.

IRUBIS GmbH, founded in 2017 and headquartered in Munich, Germany, specializes in the development of advanced mid-infrared (MIR) spectrometers and attenuated total reflection (ATR) crystals. The company integrates semiconductor technology with infrared spectroscopy to create instruments designed for real-time monitoring of bioprocesses, particularly in the pharmaceutical sector. Its offerings include a measurement system that enables online monitoring of glucose and lactate in bioreactors without contamination risk, as well as a range of ATR crystals that enhance the capabilities of Fourier transform infrared (FTIR) spectrometers. IRUBIS aims to set a new standard for online control in bioprocessing through its innovative MIR spectroscopy solutions, facilitating continuous monitoring and control of nutrient concentrations and other critical parameters in laboratory settings.

Vatorex AG is a Swiss company based in Winterthur that specializes in developing electronic solutions to combat varroa mites, a significant threat to honey bee populations. Founded in 2016, the company offers innovative products designed for hive management and monitoring. Its flagship Varroa Solution employs a hyperthermic treatment system that utilizes controlled heat to eliminate varroa mites without harming the bees. Additionally, Vatorex provides the Full Hive Kit, which includes real-time monitoring and data collection capabilities, and the Hive Manager, a mobile application for organizing hive-related information. By focusing on effective and practical treatments, Vatorex aims to enhance honey bee health and support the beekeeping industry.

Born from the MRCLEAN trial, NICO.LAB was founded in 2015 as a spin-off from the Amsterdam University Medical Center. Our research background continues to drive our way of thinking. The team consists of researchers, developers and experienced medical specialists to ensure we align with our clients needs. We believe connecting human & artificial intelligence will revolutionize emergency care. Our cloud-based solution, StrokeViewer, automatically analyses brain CT scans and gives results within minutes. StrokeViewer empowers physicians in the emergency setting to provide patients with the right treatment in time.

ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human models through advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed a suite of simulation tools known as Alya Red. This platform operates on a Software-as-a-Service model and is designed for the medical device and pharmaceutical industries. Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients, utilizing high-performance computing, computational biomechanics, and data analysis. These virtual avatars enable biomedical companies and healthcare professionals to enhance diagnostics, plan treatments, optimize drug delivery, and improve medical devices.

Dimenco B.V. is a prominent 3D technology company based in Veldhoven, the Netherlands, specializing in autostereoscopic solutions that enhance visual experiences without the need for glasses. Founded in 2010, Dimenco develops advanced 3D displays and components, alongside software and content conversion services tailored for both professional and consumer markets. The company's innovative offerings include DirectX and OpenGL visualizers that facilitate the viewing of 3D applications on their specialized displays, as well as tools like the Dimenco 3D Player for playing 3D video clips and the Dimenco Control Tool for adjusting visualization parameters. Dimenco has established itself as a leader in providing immersive and realistic visual technology, making significant strides in the realm of simulated reality.

ABCDx SA is a privately-funded company based in Geneva, Switzerland, founded in 2014 by three experts in the field of brain biomarkers. The founders include two prominent researchers from the Faculty of Medicine at the University of Geneva and the Vall d’Hebron Research Institute, who are recognized for their contributions to biomarker discovery and validation. The third founder brings extensive experience in the diagnostic and pharmaceutical industries. ABCDx specializes in the development and validation of biomarker and biomarker panel tests aimed at enhancing the diagnosis and treatment of brain injuries. The company's offerings are designed to identify and assess patients at risk of severe long-term complications stemming from traumatic injuries, strokes, and post-stroke infections. Through its innovative approach, ABCDx aims to improve patient outcomes in the realm of brain health.

Circu Li-ion is a Luxembourg-based start-up focused on automated battery disassembly and diagnostics to enhance the remanufacturing, reuse, and recycling of lithium-ion batteries. The company's proprietary platform integrates three key components: a battery library, an application layer, and robotic disassembly systems. These technologies enable significant cost reductions by decreasing dependence on manual labor and indirect expenses while achieving high levels of robot autonomy to enhance safety and efficiency. Circu Li-ion's automated processes maximize material recovery, allowing for up to 95% of battery components to be reused or recycled effectively. By employing advanced computer vision models and robotic systems, the start-up caters to the diverse designs of batteries, helping businesses reduce costs, address labor shortages, and mitigate environmental impacts associated with traditional recycling methods.

Nexdot is a company specializing in the development and production of semiconductor nanocrystals known as Quantum Dots, with a particular focus on nanoplatelets—two-dimensional nanosheet Quantum Dots that exhibit enhanced properties. Originating as a spin-off from a renowned academic laboratory in Paris, Nexdot leverages over a decade of expertise in nanomaterial research. The company has invested four years in intensive research and development to establish unique capabilities in the synthesis of colloidal Quantum Dots and Nanoplatelets. Their proprietary materials, characterized by controlled shape and composition, are designed for a variety of applications, including displays, lighting, energy storage, detectors, and bio-imaging. Nexdot combines a team of highly skilled, passionate scientists with seasoned executives who possess a strong background in management and innovation leadership, positioning the company as a leader in the field.

Tozero, founded in July 2022 in Munich, Germany, by Sarah Fleischer and Dr. Ksenija Milicevic Neumann, specializes in lithium-ion battery recycling technology. The company aims to accelerate decarbonization efforts by developing a scalable and sustainable machine for recovering critical materials such as lithium, nickel, cobalt, graphite, and manganese from various battery types. By enabling industries to reintroduce these valuable raw materials into the supply chain, Tozero contributes to more sustainable practices in battery production and reduces dependency on virgin resources.

AMT Medical B.V., established in 2015 and located in Ede, the Netherlands, specializes in the development of innovative medical devices for heart bypass surgery. The company's flagship product, the AMT Heart Bypass System, utilizes a minimal invasive technique known as the ELANA bypass, which was invented by neurosurgeon Prof. Dr. C.A.F. Tulleken and his research team. This advanced technology aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, thereby improving patient outcomes and reducing complications. AMT Medical has completed the full development of its product and the production process, with all pre-clinical trials successfully concluded. The company is also preparing to initiate a clinical multi-center trial to further validate the technology's efficacy.

Dawn Aerospace is a company that specializes in designing and manufacturing reusable spacecraft for satellite launches. Founded in 2016 and headquartered in Delft, Netherlands, with additional facilities in Auckland, New Zealand, the company offers various vehicles, including the MK-1, MK-2, MK-3, and MK-4. Dawn Aerospace is focused on developing same-day reusable launch vehicles that can operate without specialized space-launch infrastructure, allowing them to integrate seamlessly with existing air traffic. Additionally, the company provides non-toxic propulsion systems for satellites, which replace harmful fuels like hydrazine and enhance performance for small satellites and CubeSats significantly. By creating these technologies in tandem, Dawn Aerospace aims to establish an efficient, scalable, and environmentally conscious architecture for satellite deployment and operations.

Ganymed Robotics SAS, established in 2018 and headquartered in Paris, France, specializes in the development of advanced robotics technologies tailored for orthopedic surgeons. The company's primary focus is on creating a therapeutic device designed to enhance surgical precision during knee replacement procedures. This innovative technology aims to improve patient outcomes, surgeon experience, and overall efficiency of care delivery by leveraging robotic assistance to reduce operating time.